TokenPost·
Pfizer’s Elrexfio Meets Phase 3 Endpoint in Earlier-Line Myeloma Study
The trial enrolled 523 adults across 26 countries. Elrexfio’s current U.S. indication covers patients who have received at least four prior lines of therapy.
More news
- TokenPostIonQ Receives $7.5 Million for Air Force Quantum Network Phase 2
- TokenPostActuate Therapeutics Prices $11 Million Stock-and-Warrant Offering
- TokenPostDatavault AI Shares Fall 47% After Accounting and WiSA Disclosures
- TokenPostWorld Bank Mobilized $112 Billion Last Year, Banga Says Funding Remains Available
- TokenPostDeutsche Bank Says Tokenized Assets Excluding Stablecoins Could Reach $4T by 2035
- TokenPostRex and Mert Offer Opposing Views on Crypto’s Industry Outlook